Acquired Resistant Mechanism of the First-generation EGFR TKIs
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02804217
Recruitment Status : Unknown
Verified June 2016 by Yu Xinmin, Zhejiang Cancer Hospital. Recruitment status was: Recruiting
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).
Identification of Genomic Mutation Profile Using Next Generation Sequencing for Non-small-cell Lung Cancer Patients With Activating EGFR Mutations Harboring Acquired Resistance to the First-generation EGFR TKIs.
Study Start Date :
Estimated Primary Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients with NSCLC harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance
Histologically proven stage IIIB or IV non-small cell lung cancer
patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance
patients who can provide pre-treatment (EGFR TKIs) tumor tissues
patients with tumor lesions to be re-biopsy after drug resistance
patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital.
History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix